

Current Concepts and Recent Advances in Oncology: A Daylong Clinical Summit Hosted in Partnership with MOASC

A CME-MOC/NCPD-ONCC Accredited Virtual Event

New Date Saturday, May 15, 2021 | 7:30 AM – 3:30 PM Pacific Time (10:30 AM – 6:30 PM Eastern Time)

60-Minute Informal Zoom Session with Dr Neil Love to Discuss Your Patient Cases and Questions

DEADLINE TO SIGN UP FOR THIS OPPORTUNITY HAS BEEN EXTENDED TO MID-APRIL

We are pleased to announce that MOASC will once again be partnering with Dr Neil Love and his CME organization, Research To Practice (RTP), for a daylong, live educational event to take place on the newly rescheduled date of May 15, 2021. Similar in format to RTP's *Year in Review* live series, the virtual webinar will follow a multi-tumor approach with 14 expert clinical investigators reviewing current management strategies and recent advances in **breast cancer, AML/MDS, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma**. In lieu of traditional didactic lectures, the participating clinical investigator panelists will review recent data as well as review **cases provided by MOASC clinicians**. *More information regarding this session will be announced in the coming weeks including a link to register.*

In preparation for this event, RTP would like to invite MOASC community oncologists to participate in a case-based recorded 60-minute Zoom interview with Dr Neil Love, which will be utilized during the live activity. If interested in participating, please see the requirements and honoraria below:

- Must be a general medical oncologist in community-based practice.
- Have patients across the 7 oncology topics noted. Questions and cases can from your own practice, from your group's practice or on behalf of any colleagues.
- Complete the recording by April 23, 2021
- An honorarium is available to those that participate (see options below).
- **Those interested, please email us at faculty@researchtopractice.com.**

Option 1: Informally Discuss 5-10 Cases from your practice to Dr Love (some preparation required)

Honorarium offered, \$2500

- Submission of 1-3 cases per topic and 1-2 questions per case. Only a very brief case write-up will be required for each case (no more than a few lines summarizing the case itself and any accompanying questions you would like to ask the faculty panel). *If you do not have a particular case, please let us know.*
- Cases may be from your own practice, from your group practice or on behalf of a colleague.
- Case writeups must be provided 2-business days prior to scheduled interview date.
- Participate in a 1-hour, one-on-one video/audio recording (virtual) session from your home or office with Dr Love in which you will present your cases and any questions you would like the faculty to address. Recorded video clips from this discussion will be shown during the live webinar on May 15, 2021.
- Below is a list of cancers we are covering and case topics.
- **The interview with Dr Love must be completed prior to April 23, 2021.**
- Additionally, we will need to amend 10-15 minutes to your interview start time to allow for our audio engineer to optimize your video/audio connection. We will also send you one of our preferred headsets for audio quality purposes.

Option 2: Informally Discuss Practice Questions with Dr Neil Love (no preparation required)

Honorarium offered, \$1500

- Participate in a 1-hour, one-on-one video/audio recording (virtual) session from your home or office with Dr Love. Recorded video clips from this discussion will be shown during the live webinar on May 15, 2021.
- During the scheduled informal interview with Dr Neil Love, present 1-3 questions per topic and/or any cases that you would like the faculty panel to provide input on during the May 15 program.
- Questions/cases may be from your own practice, from your group practice or on behalf of a colleague.
- Below is a list of malignancies and case topics.
- **The interview with Dr Love must be completed prior to April 28, 2021.**
- Additionally, we will need to amend 10-15 minutes to your interview start time to allow for our audio engineer to optimize your video/audio connection. We will also send you one of our preferred headsets for audio quality purposes.

General Case Requirements:

Breast Cancer

- HER2-positive – *localized or metastatic*
- ER-positive, HER2-negative – *metastatic*
- Triple-negative breast cancer – *localized or metastatic*

CLL and Lymphomas

- CLL
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
- Hodgkin lymphoma

Acute Myeloid Leukemia

- Newly diagnosed not eligible for intensive therapy or with poor-risk cytogenetics
- FLT3-mutated
- IDH-mutated
- Secondary AML (to MDS or other cancer)

Myelodysplastic syndromes (MDS)

- Intermediate-risk MDS
- Higher-risk MDS

GI Cancers

- CRC – *metastatic*
- CRC - *MSI-high metastatic*
- Gastric/esophageal cancer – *localized & metastatic*
- Gastric - *Relapsed esophageal squamous cell cancer*
- Hepatocellular cancer – *advanced*
- Pancreatic cancer – *localized or metastatic*
- Cholangiocarcinoma – *advanced*
- Cholangiocarcinoma - *FGFR2 rearrangement*

GU Cancers

- Prostate cancer – *M0, metastatic CRPC, metastatic HSPC*
- Renal cell carcinoma – *advanced*
- Urothelial bladder cancer – *metastatic*
- RCC - Newly diagnosed or progression on/after immunotherapy
- UBC - High-risk non-metastatic; Progression on/after immunotherapy; FGFR alteration

Gynecologic Cancers (optional)

- Ovarian cancer
 - BRCA/HRD positive; BRCA negative
 - Multiply relapsed
- Cervical cancer – *advanced*
- Endometrial cancer – *advanced*
- Cervical - PD-L1 positive
- Endometrial - MSI-H and MSS

Lung Cancer

- Non-small cell lung cancer (NSCLC)
 - Early stage or metastatic with a targetable mutation (EGFR, ALK, etc)
 - Locally advanced or metastatic who received immunotherapy
 - Progression on/after immunotherapy
- Extensive stage small cell lung cancer

Multiple Myeloma

- Newly diagnosed – transplant eligible; transplant ineligible
- Progression after initial therapy and/or maintenance
- Multiply relapsed